[HTML][HTML] Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

…, L Ciani, L Gori, C Lazzeri, A Matucci… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Coronavirus disease 19 (COVID-19) is an emerging infectious disease
caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; …

Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4

…, F Frosali, V Querci, R Angeli, A Matucci… - Journal of Allergy and …, 2010 - Elsevier
BACKGROUND: IL-17A has been suggested to play a pathogenic role in bronchial asthma
and other allergic disorders. OBJECTIVE: Study of the relationship between human IL-17A–…

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

…, L Moja, M Cinquini, V Marino, A Matucci… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

[HTML][HTML] Eosinophils in health and disease: a state-of-the-art review

…, SK Dougan, S Berdnikovs, F Schleich, A Matucci… - Mayo Clinic …, 2021 - Elsevier
Eosinophils play a homeostatic role in the body’s immune responses. These cells are involved
in combating some parasitic, bacterial, and viral infections and certain cancers and have …

[HTML][HTML] Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

A Matucci, A Vultaggio, E Maggi, I Kasujee - Respiratory research, 2018 - Springer
Bronchial asthma (BA) is a chronic inflammatory disease with a marked heterogeneity in
pathophysiology and etiology. The heterogeneity of BA may be related to the inducing …

Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice

…, G Delogu, G Garlaschi, A Sanduzzi, A Matucci… - Autoimmunity …, 2015 - Elsevier
Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis
(PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (…

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: an EAACI statement

…, L Klimek, A Kolios, A Kothari, ML Kowalski, A Matucci… - Allergy, 2020 - Wiley Online Library
The outbreak of the SARS‐CoV‐2‐induced coronavirus disease 2019 (COVID‐19) pandemic
re‐shaped doctor‐patient interaction and challenged capacities of healthcare systems. It …

[HTML][HTML] Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders

…, UC Steiner, A Vultaggio, A Matucci… - Frontiers in …, 2019 - frontiersin.org
Background: During the past years biologic agents (also termed biologicals or biologics)
have become a crucial treatment option in immunological diseases. Numerous articles have …

Acute infusion reactions induced by monoclonal antibody therapy

E Maggi, A Vultaggio, A Matucci - Expert review of clinical …, 2011 - Taylor & Francis
This article reports recent evidence on epidemiological data concerning monoclonal antibody
(mAb) infusion-related anaphylaxis, as well as recent data on the correlation between …

[HTML][HTML] Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity

…, A Vacca, C Azzari, G Fabio, A Matucci… - The Journal of …, 2021 - jaci-inpractice.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients with
inborn errors of immunity (IEI) showed a similar infection-fatality rate, a lower incidence in …